Jefferies Group’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-1,550,700
| Closed | -$9.35M | – | 2944 |
|
|
2019
Q4 | $9.35M | Buy |
+1,550,700
| New | +$8.98M | 0.07% | 245 |
|
|
2018
Q2 | – | Sell |
-9,000
| Closed | -$33K | – | 2845 |
|
|
2018
Q1 | $33K | Buy |
+9,000
| New | +$29.5K | ﹤0.01% | 2147 |
|
|
2016
Q3 | – | Sell |
-12,600
| Closed | -$98K | – | 2562 |
|
|
2016
Q2 | $98K | Sell |
12,600
-24,700
| -66% | -$212K | ﹤0.01% | 1938 |
|
|
2016
Q1 | $288K | Buy |
+37,300
| New | +$273K | ﹤0.01% | 1694 |
|
|
2015
Q3 | – | Sell |
-9,000
| Closed | -$80K | – | 3370 |
|
|
2015
Q2 | $80K | Buy |
+9,000
| New | +$85.1K | ﹤0.01% | 2280 |
|
|
2015
Q1 | – | Sell |
-395,900
| Closed | -$4.85M | – | 2513 |
|
|
2014
Q4 | $4.85M | Sell |
395,900
-141,700
| -26% | -$1.73M | 0.03% | 436 |
|
|
2014
Q3 | $5.37M | Buy |
+537,600
| New | +$4.99M | 0.04% | 400 |
|
|
2013
Q4 | – | Sell |
-16,300
| Closed | -$49K | – | 2323 |
|
|
2013
Q3 | $49K | Buy |
+16,300
| New | +$112K | ﹤0.01% | 1773 |
|
Jefferies Group's ACHN Position: Q1 2020 in Review
Jefferies Group sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 577,179 shares — an estimated $3.48M sold.
Jefferies Group first reported a position in ACHN in Q1 2014 and held it in 12 quarters. The position peaked at $3.48M in Q4 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Jefferies Group reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Jefferies Group sold 577,179 Achillion Pharmaceuticals shares in Q1 2020, an estimated $3.48M.
- Jefferies Group first reported a position in Achillion Pharmaceuticals in Q1 2014 and held it in 12 quarters.
- Jefferies Group's Achillion Pharmaceuticals position peaked at $3.48M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Jefferies Group's 13F filing for Q1 2020, filed 15 May 2020.